Indication intelligence, analysis and sector perception

BioLife Solutions (BLFS) inks CryoStor® supply agreement

July 11, 2016 9:30am

Pre-open, the stock is up +$1.67 or +109.15 to $3.20 – SELL on the upswing, how much freeze media can be billed in a year? BLFS is barely “staying alive” having just paid 10% interest to borrow operational cash

BLFS has entered into a ten year supply agreement with Kite Pharma, a leading developer of chimeric antigen receptor (CAR) and T cell receptor (TCR) products for various cancers.

The agreement provides for KITE's supply of BioLife's CryoStor clinical grade freeze media for cells and tissues, which is embedded in it's manufacturing process for KTE-C19, a CAR T cell therapy currently in four clinical trials for various cancers.

The Bottom Line: Executes 10 year supply agreement with Kite Pharma for use in CAR T Cell therapies?? This dog has "rabies".

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 13 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.